5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma

Figure 4 Diagnostic performance of serum 5’-transfer RNA halve-lysine-CTT and combined diagnostic model in hepatocellular carcinoma. A-C: Receiver operating characteristic (ROC) curves comparing the diagnostic accuracy of serum 5’-transfer RNA halve (tiRNA)-lysine (Lys)-CTT, alpha-fetoprotein (AFP), and abnormal prothrombinogen (APT) in differentiating hepatocellular carcinoma (HCC) patients from healthy controls; D-F: ROC curves evaluating the diagnostic performance of serum 5’-tiRNA-Lys-CTT, AFP, and APT in distinguishing early-stage HCC patients from healthy controls; G: ROC curve demonstrating the combined diagnostic efficacy of serum 5’-tiRNA-Lys-CTT, AFP, and APT; H: ROC curve demonstrating the superior combined diagnostic efficacy of serum 5’-tiRNA-Lys-CTT, AFP, and APT in differentiating early-stage HCC patients from non-malignant disease. tiRNA: Transfer RNA halve; Lys: Lysine; AUC: Area under the curve; AFP: Alpha-fetoprotein; APT: Abnormal prothrombinogen; BCLC: Barcelona Clinic Liver Cancer.